Compugen Ltd CGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
-
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
-
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
-
Compugen Reports Second Quarter 2026 Results
Trading Information
- Previous Close Price
- $1.97
- Day Range
- $1.96–2.18
- 52-Week Range
- $1.43–3.24
- Bid/Ask
- $2.14 / $2.15
- Shares Outstanding
- 94.73M
- Market Cap
- $202.72M
- Volume/Avg
- 923,297 / 241,242
Key Statistics
- Price/Earnings (Normalized)
- 5.18
- Price/Sales
- 2.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://www.cgen.com
Valuation
|
Metric
|
CGEN
|
|---|---|
Price/Earnings (Normalized) | 5.18 |
Price/Book Value | 2.10 |
Price/Sales | 2.52 |
Price/Cash Flow | 5.19 |
Price/Earnings
CGEN
Financial Strength
|
Metric
|
CGEN
|
|---|---|
Quick Ratio | 5.72 |
Current Ratio | 5.72 |
Interest Coverage | — |
Quick Ratio
CGEN
Profitability
|
Metric
|
CGEN
|
|---|---|
Return on Assets (Normalized) | 27.85% |
Return on Equity (Normalized) | 47.17% |
Return on Invested Capital (Normalized) | 38.73% |
Return on Assets
CGEN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|TL#m!c | LOCK|!B?k% | $127B | |||
| Moderna Inc
MRNA
| LOCK|<kj&dnq | LOCK|C<% | $91B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#XSHX$& | LOCK|sX$< | $81B | |||
| argenx SE ADR
ARGX
| LOCK|MQDZxy | LOCK|zZ | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pv%Mbs | LOCK|k?@ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|XPnF!y | LOCK|bz^G | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KC<lz>G | LOCK|&l^@r | $27B | |||
| Incyte Corp
INCY
| LOCK|@qTWqps | LOCK|x! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lb>^Cc | LOCK|@W^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|CDfp>b | LOCK|^!G | $14B |
United States